acne
Conditions
Interventions
Single-arm clinical trial - Level I:Fire needle - skin lesion bloodletting combined external treatment, once a week, for a total of 4 treatments.
Single-arm clinical trial - Level II:Fire needle - skin lesion bloodletting combined external treatment, once a week, for a total of 4 treatments.
Single-arm clinical trial - Level III:Fire needle - skin lesion bloodletting combined external treatment. 0-1 week: twice a week
2-3 weeks: once a week. A total of 6 treatments.
Single-arm clinical trial - Level IV:Fire needle - skin lesion bloodletting combined external treatment. The treatment was given twice a week for a total of 8 times.
Control group - Level I:Red and blue light, once a week, for a total of 4 treatments.
Control group - Level II:Red and blue light, once a week, for a total of 4 treatments.
Control group - Level III:Take the Oral Moisturizing and Soothing Antipruritic Capsules (3 times a day, 4 capsules each time (0.5g per capsule), 6g per day) for 4 weeks. Use red and blue light for 0-1
Control group - Level IV:Take doxycycline orally at a dose of 100 mg per day for 2 consecutive weeks. Take Danshen Dihuan Capsules orally (3 times a day, 4 capsules each time (0.25g per capsule), 3g p
Traditional Chinese Medicine External Treatment Group - Level I:Fire needle - skin lesion bloodletting combined external treatment, once a week, for a total of 4 treatments.
Traditional Chinese Medicine External Treatment Group - Level II:Fire needle - skin lesion bloodletting combined external treatment, once a week, for a total of 4 treatments.
Traditional Chi
Sponsors
The Second Affiliated Hospital of Hunan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
16 Years to 40 Years
Inclusion criteria
Inclusion criteria: a. Age range: 16 to 40 years old, gender not restricted. b. Clinically diagnosed with common acne, with severity classified as mild to moderate (I-IV grades). Acne grade III in traditional Chinese medicine diagnosis is characterized by damp heat in the spleen and stomach, and acne grade IV is characterized by stasis and blood stasis accumulation. c. Those who have received conventional acne treatment but with poor results, or those whose condition recurs frequently, or those who cannot take oral medications for various reasons. d. Two weeks before enrollment, no conventional acne treatment (medication or physical therapy) was used. During the study period, no other drugs or therapies for treating acne were used. e. No participation in other clinical trials within 3 months before enrollment and during the study period. f. The patient has fully understood the study protocol, possible risks, and postoperative care requirements. g. Informed consent, voluntary participation, regular follow-up and consultation, authorization for the use of desensitized diagnosis and imaging data for teaching and research, and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: a. Special types of acne, such as severe conglobate acne, fulminant acne, etc. b. Pregnant women or those planning to become pregnant in the near future. c. Those with severe organic diseases, systemic diseases, mental disorders, or other diseases that the researchers consider unsuitable for inclusion in the study. d. Those with a scar-prone constitution or a history of hypertrophic scars or keloids. e. Those with bleeding disorders, or those using anticoagulant or antiplatelet drugs. f. Those with a clear history of allergy to iodophor, alcohol, acidic preparations, metal needles or excipient ingredients. g. Those who cannot cooperate with treatment for various reasons or do not wish to follow up and visit the doctor regularly. h. Those with abnormal liver and kidney functions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global Acne Grading System (GAGS) score;The Global Acne Grading System (GAGS) improvement;Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Global Acne Grading System (GAGS) improvement;Improvement rate of the Global Acne Grading System (GAGS);Treatment effectiveness rate;Improvement rate of lesion count;Improvement rate of lesion score;CBS Cloud Mirror Detection;Skin physicochemical index difference;No recurrence period;recurrence rate; | — |
Countries
China
Contacts
Public ContactWang Haizhen
The Second Affiliated Hospital of Hunan University of Chinese Medicine
Outcome results
None listed